JP2019528271A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528271A5
JP2019528271A5 JP2019508842A JP2019508842A JP2019528271A5 JP 2019528271 A5 JP2019528271 A5 JP 2019528271A5 JP 2019508842 A JP2019508842 A JP 2019508842A JP 2019508842 A JP2019508842 A JP 2019508842A JP 2019528271 A5 JP2019528271 A5 JP 2019528271A5
Authority
JP
Japan
Prior art keywords
composition
gene
deletion
smallpox
chikungunya
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019508842A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528271A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2017/050879 external-priority patent/WO2018032057A1/en
Publication of JP2019528271A publication Critical patent/JP2019528271A/ja
Publication of JP2019528271A5 publication Critical patent/JP2019528271A5/ja
Pending legal-status Critical Current

Links

JP2019508842A 2016-08-19 2017-08-18 ウイルスワクチン Pending JP2019528271A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903295A AU2016903295A0 (en) 2016-08-19 Viral Vaccines
AU2016903295 2016-08-19
PCT/AU2017/050879 WO2018032057A1 (en) 2016-08-19 2017-08-18 Viral vaccines

Publications (2)

Publication Number Publication Date
JP2019528271A JP2019528271A (ja) 2019-10-10
JP2019528271A5 true JP2019528271A5 (enExample) 2020-05-14

Family

ID=61195904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508842A Pending JP2019528271A (ja) 2016-08-19 2017-08-18 ウイルスワクチン

Country Status (18)

Country Link
US (2) US10905759B2 (enExample)
EP (2) EP3500280A4 (enExample)
JP (1) JP2019528271A (enExample)
KR (1) KR20190050787A (enExample)
CN (1) CN109862909A (enExample)
AR (1) AR110624A1 (enExample)
AU (1) AU2017313450B2 (enExample)
CA (2) CA3034282A1 (enExample)
CL (1) CL2019000405A1 (enExample)
IL (1) IL264893B (enExample)
MA (1) MA45994A (enExample)
MX (1) MX2019001919A (enExample)
MY (1) MY200887A (enExample)
NZ (1) NZ750578A (enExample)
SG (1) SG11201900814QA (enExample)
TW (1) TWI728173B (enExample)
WO (1) WO2018032057A1 (enExample)
ZA (1) ZA201900641B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870217A4 (en) * 2018-10-22 2022-08-31 Icellkealex Therapeutics LLC MUTANT VACCINIA VIRUSES AND USE THEREOF
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
CN112362877B (zh) * 2020-10-27 2024-04-12 江苏先声医学诊断有限公司 一种mbp重组蛋白以及其应用
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298370T1 (de) * 1994-04-29 2005-07-15 Baxter Healthcare Sa Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen
CN1418951A (zh) * 2001-05-23 2003-05-21 广州绿健生物技术有限公司 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法
ATE315660T1 (de) * 2002-05-16 2006-02-15 Bavarian Nordic As Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
KR20120002613A (ko) * 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
KR20040015624A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물
ATE403005T1 (de) * 2003-02-18 2008-08-15 Helmholtz Zentrum Muenchen Rekombinantes mva und verfahren zur erzeugung davon
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
EP1683870A1 (en) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
JP2013538577A (ja) * 2010-09-23 2013-10-17 バクスター・インターナショナル・インコーポレイテッド 組み換えウイルスベクターおよび黄熱病ウイルスに対する免疫反応を惹起するための方法
MY193724A (en) * 2013-03-15 2022-10-27 Sementis Ltd Immune modulation
RS57290B1 (sr) * 2013-11-01 2018-08-31 Sementis Ltd Proizvodnja virusnih vektora
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus

Similar Documents

Publication Publication Date Title
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
JP2019528271A5 (enExample)
CA2422094C (en) Vaccination method
Herbert et al. Recombinant adenovirus expressing the haemagglutinin of peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR
JP2016510989A5 (enExample)
Webster et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
BR112018076633A2 (pt) mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿uk
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
CA2408328A1 (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
Mendes et al. Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1
JP2011041578A5 (enExample)
JP4700907B2 (ja) ウイルス増殖方法
Weyer et al. Poxvirus-vectored vaccines for rabies—a review
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
EP1881845A2 (en) Nipah virus vaccines
JP2022509221A5 (enExample)
MX2017016273A (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante.
JP2016074727A5 (enExample)
WO2008097267A2 (en) Vaccines against vesicular stomatitis
RU2015115785A (ru) Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака
JP2010523138A5 (enExample)
Denzler et al. Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques
Kyriakis Tomorrow’s vector vaccines for small ruminants
Akkutay-Yoldar et al. Diagnosis and phylogenetic analysis of orf virus in Aleppo and Saanen goats from an outbreak in Turkey
EA200701801A1 (ru) Применение модифицированных поксвирусов для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов